Shenzhen Osce Biotechnology

Shenzhen Osce Biotechnology is a biopharmaceutical company headquartered in Shenzhen, China, dedicated to the discovery and development of innovative small molecule drugs, with a core focus on Targeted Protein Degradation (TPD). The company utilizes its proprietary PROTAC platform to develop therapies for oncology, particularly targeting hormone-related cancers such as prostate and breast cancer. By focusing on previously "undruggable" proteins, Osce Biotechnology aims to provide next-generation treatment options for patients with resistant or refractory diseases. The firm integrates medicinal chemistry, structural biology, and pharmacology to accelerate its pipeline from discovery to clinical proof-of-concept.